logo-loader
viewAvacta Group PLC

Avacta's CEO to Present at Biotech Investor Day

/**/ sup{font-size:80%}link{ color: blue }visited{ color: #954F72 } .r{size:595.0pt 842.0pt;margin:69.25pt 42.15pt 49.65pt 70.9pt;}div.r{}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 12.0pt; margin-left: 0cm; margin-right: 9.05pt; margin-top: 0cm; text-align: right}span.bo{font-size:11.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.br{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: center}span.bm{font-size:10.0pt;line-height:115%; font-family:"Arial","sans-serif"}p.bs{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: center}p.bt{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-right: 9.2pt; text-align: center}span.bj{font-size:11.0pt;line-height:115%; font-family:"Arial","sans-serif"}p.bu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:9.05pt;margin-bottom: 12.0pt;margin-left:0cm;text-align:justify;line-height:115%} span.bh{font-size:11.0pt; line-height:115%;font-family:"Arial","sans-serif"}span.bg{font-size:11.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black}span.bf{font-size:11.0pt; line-height:115%;font-family:"Arial","sans-serif";color:black}p.bv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-right:9.2pt;text-align:justify;line-height: 115%}span.bd{font-size:11.0pt;line-height:115%;font-family: "Arial","sans-serif"}span.bc{font-size: 11.0pt;line-height:115%;font-family:"Arial","sans-serif"}p.bw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-right:9.2pt;line-height:115%}p.bx{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; text-align: center}p.by{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%}table.bz{margin-left:-5.4pt;border-collapse:collapse} tr.ap{height:59.95pt}td.au{width:237.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:59.95pt}p.ca{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; text-align: justify}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:115%}p.cc{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm}td.ar{width:187.25pt;padding:0cm 5.4pt 0cm 5.4pt; height:59.95pt}p.cd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:9.2pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;line-height:115%}span.at{font-size:11.0pt;line-height:115%; font-family:"Arial","sans-serif";color:black}td.aq{border:none;padding:0cm 0cm 0cm 0cm}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";} tr.ag{height:119.8pt}td.al{width:237.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:119.8pt}p.ce{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:16.0pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height: 115%}span.ao{font-size:11.0pt;line-height: 115%;font-family:"Arial","sans-serif";color:black}p.cf{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:9.2pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height: 115%}td.ah{width:187.25pt;padding:0cm 5.4pt 0cm 5.4pt; height:119.8pt}p.cg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";line-height: 115%; margin-bottom: 0cm; text-align: justify; text-decoration: underline}span.ch{font-family:"Times New Roman","serif";color:blue;text-decoration:underline;color: black; font-family: "Arial","sans-serif"; font-size: 11.0pt; line-height: 115%; text-decoration: none}p.ci{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 9.2pt; margin-top: 0cm; text-align: right}tr.ab{height:95.5pt} td.ad{width:237.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:95.5pt}span.af{font-size:11.0pt;line-height:115%;font-family: "Arial","sans-serif";color:black}p.cj{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; margin-left: 0cm; margin-right: 16.0pt; margin-top: 0cm; text-align: justify}td.ac{width:249.75pt;padding:0cm 5.4pt 0cm 5.4pt; height:95.5pt}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 12.1pt; text-align: justify}p.cl{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;text-align:justify;line-height:115%}a.y{font-weight: bold}span.w{font-size:11.0pt;line-height: 115%;font-family:"Arial","sans-serif"}span.v{color: blue; text-decoration: underline}p.cm{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 6.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 12.1pt} span.u{font-size: 11.0pt;line-height:115%;font-family:"Arial","sans-serif";color:black}span.s{font-size:11.0pt;font-family:"Arial","sans-serif"} /**/
RNS Number : 9227G
Avacta Group PLC
29 July 2019
 

29 July 2019

Avacta Group plc

("Avacta", the "Company" or the "Group")

 

Avacta's Chief Executive Officer to Present at the Solebury Trout European Biotech Investor Day in New York

Avacta Group plc (AIM: AVCT), a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer® platform, is pleased to announce that its Chief Executive Officer, Dr Alastair Smith, will present at the European Biotech Investor Day in New York City in the New York Times building on Thursday, August 1st organised by Solebury Trout and sponsored by Goodwin LLC, Deutsche Bank, H.C. Wainwright and Nasdaq.

Alastair's presentation will discuss the Company's drug development pipeline based on the combination of Affimer immunotherapies with tumour targeted chemotherapy aimed at addressing the lack of a durable response to current immunotherapies experienced by most cancer patients.

The presentation will be made available on the Company's website: https://www.avacta.com/investors/documents.

- Ends -

 

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Giles Rolls - Corporate Finance

Tim Redfern - ECM

 

WG Partners (Joint Broker)

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

 

Turner Pope Investments

James Pope / Ben Turner

 

Yellow Jersey PR (Financial Media and IR)

Sarah Hollins

Harriet Jackson

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0) 203 621 4120

www.turnerpope.com

 

 

Tel: +44 (0)7764 947 137

Tel: +44 (0)7544 275 882

[email protected]

 

Tel: +44 (0)7787 502 947

[email protected]

 

 

About Avacta Group plc - https://www.avacta.com

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients.

 

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn.  Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost. 

 

Avacta's proprietary targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. 

 

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first programme into the clinic in the first half of 2020.

 

Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., and a deal with LG Chem worth up to $310m, and actively seeks to license its proprietary platforms in a range of therapeutic areas. The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

About the European Biotech Investor Day 

The European Biotech Investor Day in NYC, features privately-held and EU-listed biotechnology companies representing the "Next Wave of Opportunities" emerging from Europe.
Participating companies offer compelling or novel approaches to addressing a range of indications. To inquire about Solebury Trout or to attend the event, please contact Thomas Hoffman at [email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRALLFSSDTIRFIA

Quick facts: Avacta Group PLC

Price: 19.625

Market: AIM
Market Cap: £34.53 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half. Stacey says alongside the recent...

3 weeks ago

RNS

Holding(s) in Company

2 days, 15 hours ago

Holding(s) in Company

5 days, 4 hours ago

Holding(s) in Company

5 days, 4 hours ago

Holding(s) in Company

6 days, 9 hours ago

Holding(s) in Company

6 days, 11 hours ago

Result of General Meeting

1 week, 2 days ago